Case Control in Sarcopenia Among Elderly Type 2 Diabetic Patients

Asessment of Sarcopenia Among Elderly Type 2 Diabetic Patients

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07244601

Enrollment

100

Registered

2025-11-24

Start date

2025-12-22

Completion date

2028-10-20

Last updated

2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia

Brief summary

1. Assess sarcopenia prevalence in elderly diabetic patients. 2. Evaluate impact of diabetes and its medications on muscle health. 3. detect effect of sacropenia on quality of life on elderly

Interventions

DIAGNOSTIC_TESTmuscle ultrasound

Bedside muscle ultrasound to measure muscle thickness, cross-sectional area and echogenicity

Study design

Observational model

CASE_CONTROL

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

65 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

1. Inclusion criteria: The study will included all patient ,age ≥ 60 years,diagnosed with type 2 diabetes mellitus at least 5 years duraation according to ADA guideline referance(8) (diabetes can be made if a patient's A1C is 6.5% or higher, their FPG is 126 mg/dL or higher, or their 2-hour plasma glucose during an OGTT is 200 mg/dL or higher. A random plasma glucose of 200 mg/dL or higher, in conjunction with classic symptoms of hyperglycemia, also indicates diabetes) ●Able to give informed consent 2.

Exclusion criteria

* chronic renal disease * chronic liver disese * Severe cognitive impairment * Known neuromuscular diseases affecting mobility * malignancy Data of the study will collected over one year duration from 1/2026 \_1/2027

Design outcomes

Primary

Measure	Time frame	Description
Prevalence of sarcopenia assessed by muscle ultrasound in elderly diabetic	Within 6 months from the start of recruitment.	Sarcopenia will be evaluated using muscle ultrasound to measure muscle thickness and echo intensity of the quadriceps muscle. The results will be interpreted according to EWGSOP2 diagnostic criteria, which combine muscle mass and muscle strength parameters
Assessment of muscle strength using handgrip dynamometry	Within 6 months	Handgrip strength will be measured using a handheld dynamometer, and the average of three attempts for the dominant hand will be recorded.

Secondary

Measure	Time frame	Description
Quality of life score using the SarQoL questionnaire.	Within 6 months.	Quality of life related to sarcopenia will be evaluated using the validated SarQoL questionnaire.

Contacts

Primary Contacteman alaa eldean, master degree

emanalaa359@gmail.com2+01098614329

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026